NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

微針給藥系統市場:2021年∼2026年前的預測

Microneedle Drug Delivery System Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023230
出版日期 內容資訊 英文 85 Pages
商品交期: 最快1-2個工作天內
價格
微針給藥系統市場:2021年∼2026年前的預測 Microneedle Drug Delivery System Market - Forecasts from 2021 to 2026
出版日期: 2021年07月07日內容資訊: 英文 85 Pages
簡介

在預測期內,全球微針給藥系統市場將以7.40% 的複合年增長率增長,從2019年的111,219,000美元增長到2026年的 183,372,000美元。

本報告提供全球微針給藥系統市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,各類型,各應用領域,各地區的市場規模的變化與預測,競爭情形,並提供主要企業簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 假設

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 產業的競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 各微針頭類型的微針給藥系統市場分析

  • 簡介
  • 中空微針頭
  • 固型微針頭
  • 溶解性微針頭
  • 塗料型微針頭
  • 水凝膠型微針頭

第6章 各應用領域的微針頭藥物輸送系統市場分析

  • 簡介
  • 神經學的狀態
  • 心血管
  • 皮膚科
  • 其他

第7章 各地區的微針給藥系統市場分析

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 中東和非洲
  • 亞太地區

第8章 競爭環境與分析

  • 主要的企業與策略分析
  • 新興企業和市場收益性
  • 合併,收購,協定,及合作
  • 供應商的競爭力矩陣

第9章 企業簡介

  • LTS Lohmann Therapie-Systeme AG
  • Nissha Co. Ltd.
  • ASTI Corporation
  • AdminMed nanoBioSciences LLC
  • Micron Biomedical Inc.
  • Raphas Co. Ltd.
  • Micropoint Technologies
  • 3M
  • MiNDERA Corporation
  • MyLife Technologies

清單不網羅性

目錄
Product Code: KSI061611628

The global microneedle drug delivery systems market is expected to grow at a compound annual growth rate of 7.40% over the forecast period to reach US$183.372 million in 2026 from US$111.219 million in 2019. Microneedles are used as a drug delivery system primarily designed for facilitating percutaneous drug delivery. However, currently, microneedles in addition to percutaneous drug delivery have been considered as an efficient technique facilitating ocular, oral mucosal, gastrointestinal, ungual, and vaginal drug administration. The drug is held in a reservoir adjacent to the microneedles. Microneedles are designed to be applied to the skin like a patch which when applied creates microscopic pores and crosses the outermost layer of the skin. The extremely small size of the needles allows the dermal nerves and blood vessels to not be damaged, thus, making the administration of the drug-using microneedles painless. The growth in the microneedle drug delivery system may be attributed to the growing preference for non-invasive drug delivery mechanisms. Simultaneously, the improved bioavailability with the maintenance of relatively constant plasma concentrations will also boost the market for the Microneedles drug delivery system during the forecast period. However, new developments in biotechnology for drug delivery such as microfabricated needles will also be responsible for the growth of the market during the given time frame.

Microneedles for transdermal delivery.

A transdermal delivery system can allow sustained release of the drug by bypassing the first-pass effect. There has been a rise in the advancement and innovation in formulation technologies, which are expected to enhance the drug loading capabilities and abilities of microneedles. Digital technology and 3D printing contribute to the enhancement of microneedle fabrication technology. To date, several studies and research on the aspects of microneedles, for the Vivo transdermal drug delivery system have been conducted. For instance, Griffin et al. had conducted a trial and study evaluating excipient coated and uncoated microneedles in eighteen health volunteers, between the year 18 to 45 years. The results stated that the microneedles didn't induce any major or unexpected side effects, and only resulted in the minimum level of pain. Other institutions and organizations have also been making a significant impact in the market. For instance, Tan et al. conducted and studies the treatment of keloids using in around 28 volunteers in phase one trial. The trial was conducted using hyaluronic acid-based microneedle and the results stated that the treatment with a microneedle system could serve and be used as an alternative when conventional treatments, are not suitable for the volunteers or the patient.

Increasing prevalence of diabetes.

The market is expected to surge in the coming years, due to the increasing prevalence of diabetes, globally. According to the International Diabetes Federation, around 463 million adults had been living with diabetes in the year 2019, and the number has been expected to rise to 700 million, by the year 2045. Diabetes had caused around 4.2 million deaths in 2019. Microneedles have been proving to be an effective way to provide and deliver insulin based on the level of glucose in a patient's body. In March 2020, a research team, which was led by a UCLA bioengineering professor, had created a novel and coin sizes adhesive polymer patch with the use of microneedles. This development is expected to have a positive impact on the market in the coming years.

Latest Developments.

Major companies and organizations have been making significant developments in the market, in the past few years.

In June 2021, TSRL and PharmaTher announced that they had teamed up to develop microneedles patches. The novel partnership and collaboration would be used to collect and pool resources and intelligence to develop intradermal delivery devices for their use in therapeutic areas of field and focus. Both the companies had been involved in the development of the microneedle delivery system. PharmaTher had licensed microneedle technology from the University of California in the year 2020, and TSRL had been working on microneedle prototype patches, with support from the reputed National Institute of Allergy and Infectious Diseases.

In June 2021, The Austrian Institute of Technology announced the partnership with In-Vision and DirectSens, to launch the NUMBAT research project, to leverage high-resolution DLP 3D printing to develop an array and group of polymeric microneedles for less painful, and minimally invasive glucose monitoring. Glucose monitoring is highly essential for people with diabetes. This development is expected to have a positive impact on the market, in the coming years.

In June 2021, Aesthetics Biomedical, a major developer of aesthetics devices, announced that it had received FDA clearance for its Vivace RF Micro-needling device, which would be used in both 1MHz and 2MHz frequency. The novel micro-needling technology had been designed and developed to provide patients with brighter radiant skin.

Market Segmentation:

  • By Microneedle Type
  • Hollow microneedle
  • Solid microneedle
  • Dissolving microneedle
  • Coated microneedle
  • Hydrogel-forming microneedle
  • By Applications
  • Neurologic Conditions
  • Cardiovascular
  • Dermatology
  • Others
  • By Geography
  • North America
  • South America
  • Europe
  • Middle East and Africa
  • Asia Pacific

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Microneedle Drug Delivery Systems Market analysis, By Microneedle Type

  • 5.1. Introduction
  • 5.2. Hollow microneedle
  • 5.3. Solid microneedle
  • 5.4. Dissolving microneedle
  • 5.5. Coated microneedle
  • 5.6. Hydrogel-forming microneedle

6. Microneedle Drug Delivery Systems Market analysis, By Applications

  • 6.1. Introduction
  • 6.2. Neurologic Conditions
  • 6.3. Cardiovascular
  • 6.4. Dermatology
  • 6.5. Others

7. Microneedle Drug Delivery Systems Market analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
  • 7.3. South America
  • 7.4. Europe
  • 7.5. Middle East and Africa
  • 7.6. Asia Pacific

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. LTS Lohmann Therapie-Systeme AG
  • 9.2. Nissha Co. Ltd.
  • 9.3. ASTI Corporation
  • 9.4. AdminMed nanoBioSciences LLC
  • 9.5. Micron Biomedical Inc.
  • 9.6. Raphas Co. Ltd.
  • 9.7. Micropoint Technologies
  • 9.8. 3M
  • 9.9. MiNDERA Corporation
  • 9.10. MyLife Technologies

List is not exhaustive